Oppenheimer began coverage on shares of Personalis (NASDAQ:PSNL) in a report released on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $29.00 target price on the stock. Oppenheimer also issued estimates for Personalis’ Q2 2019 earnings at ($0.32) EPS, Q3 2019 earnings at ($0.23) EPS, Q4 2019 earnings at ($0.24) EPS, FY2019 earnings at ($1.03) EPS, Q1 2020 earnings at ($0.26) EPS, Q2 2020 earnings at ($0.24) EPS, Q3 2020 earnings at ($0.20) EPS, Q4 2020 earnings at ($0.16) EPS, FY2020 earnings at ($0.87) EPS and FY2021 earnings at ($0.48) EPS.
A number of other analysts have also weighed in on PSNL. Bank of America set a $68.00 price objective on Inphi and gave the company a buy rating in a research note on Monday. Morgan Stanley set a $70.00 price objective on Edison International and gave the company a hold rating in a research note on Monday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $28.25.
NASDAQ:PSNL opened at $21.40 on Monday. Personalis has a fifty-two week low of $20.21 and a fifty-two week high of $31.88.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.